Egypt: Drug Price Hikes Highlight Market Volatility

ConclusionDespite its longer-term potential, profitability in the Egyptian pharmaceutical industry remains constrained by tight price controls. Efforts to ease the pressure on drug makers with the gradual introduction of an ERP system, have increased the burden of medicine costs on the general public and failed to shield pharmaceutical companies from economic turbulence. Government reassurances that the populous will be protected from the worst effects of structural reforms  sound increasingly vacuous in the face of double-digit inflation and ongoing drug shortages.  Government expenditure on health as a percentage of total government expenditure was a paltry 6% in 2014 – unchanged since pre-2011 (WHO). In the absence of adequate health insurance to protect individ uals from spiking medicine costs, the government will come under intense pressure to commit much higher levels of public finance to help improve access to medicines while the economy stabilizes.Related Content: AMNOG and the German Reforms: What Will Change?BREXIT: Is the Pharmaceutical Industry at Risk?Using Data-Driven Insights and Analytics to Drive Decision MakingAdaptability: Using Change for Competitive AdvantageBanner Ad: Banner URL: http://social.eyeforpharma.com/users/preeti-patel-and-sophie-schmitzPr écis: Profitability in the Egyptian pharmaceutical industry remains constrained by tight price controlsPremium`: Freemium`: Channels: ColumnTags: pricingPricing an...
Source: EyeForPharma - Category: Pharmaceuticals Authors: Source Type: news